About us Contacts Drug interactions: 390 212
Drug search by name

Copiktra and PCE Dispertab

Determining the interaction of Copiktra and PCE Dispertab and the possibility of their joint administration.

Check result:
Copiktra <> PCE Dispertab
Relevance: 17.06.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Erythromycin may increase the blood levels of duvelisib in some patients. This may increase the risk and/or severity of serious side effects such as diarrhea, inflammation of the intestine or lungs, low white blood cell and platelet counts, infections, skin reactions, and liver problems. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme. When a single 10 mg oral dose of duvelisib was coadministered with the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 5 days) in 16 healthy study subjects, duvelisib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.7- and 4-fold, respectively. Based on physiologically-based pharmacokinetic (PBPK) modeling and simulation, the increase in duvelisib exposure is estimated to be approximately 2-fold at steady state during coadministration with potent CYP450 3A4 inhibitors. The extent to which other, less potent CYP450 3A4 inhibitors may affect duvelisib is unknown. PBPK modeling and simulation estimated no effect on duvelisib exposure from concomitantly used mild or moderate CYP450 3A4 inhibitors.

MANAGEMENT: Caution is advised when duvelisib is used with CYP450 3A4 inhibitors. Patients should be monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.

References
  • "Product Information. Copiktra (duvelisib)." Verastem, Inc., Needham, MA.
Copiktra

Generic Name: duvelisib

Brand name: Copiktra

Synonyms: n.a.

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction